Novo Nordisk set to launch weight-loss drugs in more countries but in constrained fashion, CEO says
Medical

Novo Nordisk set to launch weight-loss drugs in more countries but in constrained fashion, CEO says

Staff Reporter 950 Views 0 Comments

It’s been well documented how Novo Nordisk has had difficulty in meeting the soaring demand for its GLP-1 weight loss treatments. | Amid supply problems, Novo Nordisk plans to launch its GLP–1 drugs in “more and more” countries, CEO Lars Fruergaard Jørgensen said at a recent Reuters event, though he added that the launches will be “constrained.” Meanwhile on Monday, another maker of GLP-1 diabetes drugs, Eli Lilly, will face shortages of Trulicity in Europe through September, according to the European Medicines Agency.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source

Leave a Reply